P3431 - Survival Analysis of Early Onset Pancreatic Cancer: A SEER study (2016-2021)

Sheena Bhushan, MD¹, Abijha Boban, DO, MBA², Lisa Gambini, MPH², Jaskaranpreet Kaur, MD, MS³, Oluseyi Abidoye, MD^4
1Northeast Georgia Medical Center, Buford, GA; ²Northeast Georgia Medical Center, Atlanta, GA; ³North Alabama Medical Center, Florence, AL; ⁴Mayo Clinic, Phoenix, AZ

Introduction: The incidence of early onset pancreatic adenocarcinoma in individuals younger than 50 years is rapidly rising. Mean survival times (MST) were studied for various demographics to determine where the focuses of research should be to improve survival outcomes.



Methods: Using the Surveillance, Epidemiology, and End Results (SEER) Program Research Plus database individuals with pancreatic adenocarcinoma confirmed by histology were identified (2016-2021). Additional variables including demographics, survival months, median income, race, and gender were also included. Data were analyzed using Kaplan-Meier survival analysis, and the Breslow test. Cox proportional hazards regression analysis assessed the impact of various variables on survival time (in months) among patients with early onset pancreatic cancer.

Results: Of the 417 individuals, majority were White 70.7% (n=295), followed by Asian/Pacific islander at 15.3% (n=64), Blacks at 12% (n=50) and American Indian/Alaskan at 1.9% (n=8). Majority were diagnosed at Stage 4 65.5% (n=273) followed by Stage 3 12.9% (n=54), Stage 2 12.5% (n=52) and Stage 1 12.5% (n=52). Comparison of survival times across different groups revealed that Whites had the longest MST in months (18.63), followed by American Indian/Alaska Native, (16.63), Blacks (15.12), and Asians (14.96), however no significant differences in median survival times were noted (χ²(3) = 1.162, p = .762). Female gender showed longer survival time in months (mean 19.08, median 12) compared to males (mean 16.4, median 10), which was found to be a significant difference (χ²(1) = 4.704, p = .030). Finally, mean survival was longest in Stage 3 (31.99), followed by Stage 1(28.81) , stage 2 (27.81), and Stage 4 (10.72). Breslow test showed significance (χ²(3) = 81.907, p < .001) in the median survival with longest in Stage 3 (23) and shorted in stage 4 (7). In the hazard regression analysis, the overall model was statistically significant, χ²(12) = 84.444, p < .001. Cancer staging was the only significant predictor of survival, χ²(3) = 67.401, p < .001. Compared to Stage 1, the hazard of mortality was significantly higher for Stage 3 (HR = 2.888, 95% CI [1.842, 4.527], p < .001), while stage 2 and 4 were not statistically significant.

Discussion: Men had lower MST as compared to women, which is consistent with late onset pancreatic cancer, which could be due to biological differences among men and women at all ages. Higher stage cancer had lower MST likely due to a late presentation and diagnosis.


Disclosures:


Sheena Bhushan, MD¹, Abijha Boban, DO, MBA², Lisa Gambini, MPH², Jaskaranpreet Kaur, MD, MS³, Oluseyi Abidoye, MD⁴. P3431 - Survival Analysis of Early Onset Pancreatic Cancer: A SEER study (2016-2021), ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.